A shift in medical classification could open a fresh avenue for Novo Nordisk’s GLP-1 franchise, even as the Danish drugmaker grapples with accelerating patent erosion in key emerging markets. On May 12, 2026, an international research network officially renamed Polycystic Ovary Syndrome (PCOS) as Polyendocrine Metabolic Ovarian Syndrome (PMOS), placing greater emphasis on the metabolic dimension of the disorder. That matters for Novo because semaglutide, the active ingredient in Ozempic and Wegovy, may fit directly into the new treatment framework. A companion study found that semaglutide slashed testosterone levels in affected women by 51%, provided they achieved a weight loss of at least 10%. With one in eight women worldwide affected by the condition, the addressable population is vast — although a dedicated FDA approval for PMOS remains a distant prospect. For now, patients could gain access off-label through comorbidities such as type 2 diabetes or fatty liver disease.
The timing is critical because Novo is losing pricing power in parts of the world where obesity and diabetes are growing fastest. Brazil’s health regulator Anvisa has approved Ozivy, the first locally produced injectable semaglutide analogue, manufactured by EMS in São Paulo state. Ozempic lost its patent exclusivity in Brazil in March, and EMS intends to undercut the branded product by roughly 30%. The lowest dose is expected to cost around 630 reais. EMS plans to produce 350,000 pre-filled pens initially across three doses and target 1.2 million sold units in the first year, generating over 500 million reais in revenue. Brazil is not an isolated case: generic semaglutide hit the Indian market in March, prompting Novo to cut prices there, and Canada has also cleared generics. The patent runway is shortening in India, China, Brazil, Turkey, South Africa and Canada — countries that together represent a huge share of the global population and future demand for weight-loss and diabetes therapies.
Investors have already voted with their feet. Novo Nordisk shares closed at €39.05 on Friday, a decline of 35.7% over the past twelve months. The RSI sits at 47.6, near neutral territory. On a brighter note, the stock has rallied 13.06% over the past month, suggesting some opportunistic buying after the deep sell-off. Yet the broader analyst community remains cautious. Of 19 houses covering the stock, 13 rate it “Hold” or “Neutral”. Deutsche Bank’s Emmanuel Papadakis keeps a “Neutral” rating with a 290 DKK target, while Jefferies’ Michael Leuchten is also on “Neutral” at 270 DKK. The seven major US banks — Bernstein, BMO Capital, Goldman Sachs, Morgan Stanley, JPMorgan, Citigroup and TD Cowen — average a price target of 247 DKK and uniformly carry hold or sell recommendations.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Underlying the caution is a dual challenge: pricing pressure in the US and limited visibility on the pipeline after the CagriSema setback. The competitive threat from Eli Lilly is intensifying — Lilly’s Retatrutide, which can deliver up to 30% weight loss, is advancing in Phase 3 and sets the industry benchmark. Moreover, Lilly secured FDA approval in early April for Foundayo, an oral obesity drug, ending Novo’s brief monopoly in the US oral weight-loss pill market. Novo’s own quarterly figures offered some relief: first-quarter adjusted operating profit came in at 32.86 billion Danish kroner, comfortably ahead of the consensus estimate of 28.74 billion. But the full-year guidance remains defensive. On a currency-adjusted basis, the company now expects revenue and adjusted operating profit to decline by 4% to 12%, a corridor that has only been narrowed, not improved.
Management is trying to support the stock through a hefty buyback programme. Between May 18 and 22, Novo repurchased 1.05 million B-shares, bringing the total bought since February to 17.05 million B-shares at a cost of 4.47 billion Danish kroner, or an average price of 262.22 kroner per share. The company now holds 34.2 million of its own shares, equivalent to 0.8% of the share capital. The current sub-programme runs until February 1, 2027 and allows for buybacks worth just over 11.2 billion kroner, part of a broader 12-month authorisation of up to 15 billion kroner. While the repurchases provide a technical floor, they do not resolve the fundamental tension between pipeline promise and competitive reality.
The next major test for the stock comes soon. Novo is presenting research and development strategy at the American Diabetes Association conference on June 7, 2026, followed by first-half results on August 5. The ongoing ASCO meeting may also yield additional data on broader GLP-1 applications. Whether the pipeline — including a potential oral Wegovy — can offset the rapid erosion of patent protection in large swathes of the world will determine if the stock can halt its slide. The new PMOS definition offers a tantalising label expansion opportunity, but it will take years to convert that into approved revenue. In the meantime, the patent clock is ticking louder in São Paulo, Mumbai and beyond.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from May 31 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 31.
Novo Nordisk: Buy or sell? Read more here...
